daprodustat
A member of the class of barbiturates that is barbituric acid substituted by cyclohexyl groups at positions 1 and 3, and by a (carboxymethyl)aminocarbonyl group at position 5. It is an inhibitor of hypoxia-inducible factor prolyl hydroxylase developed by GlaxoSmithKline for the treatment of anaemia in patients with chronic kidney disease.
Machine-generated and unreviewed. Identity, structure and cross-references come straight from ChEBI's and CARD's own data; no curator has signed off on this record yet.
Classification
Chemical structure
| Molecular formula | C19H27N3O6 |
|---|---|
| Charge | 0 |
| Average mass | 393.44 Da |
| Monoisotopic mass | 393.18999 Da |
| Source | ChEBI |
| InChIKey | RUEYEZADQJCKGV-UHFFFAOYSA-N |
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,15H,1-11H2,(H,20,25)(H,23,24)
Also called
- Jesduvroq
- daprodustatum
- N-[(1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidin-5-yl)carbonyl]glycine
- GSK 1278863
- GSK-1278863
- GSK1278863
- {[(1,3-dicyclohexyl-2,4,6-trioxohexahydropyrimidin-5-yl)carbonyl]amino}acetic acid
Cross-references
Drug registries
Patents and articles
Activity roles
- antiviral agent
CHEBI:22587
Source concepts
| Source | Native ID | Label | Minted CURIE | Version |
|---|---|---|---|---|
| CHEBI | CHEBI:229223 |
daprodustat | antibioticmech:chebi-4e985a16ff |
2026-08-30 |
Mechanism summary
- Clinical status
- APPROVED
Curation history
-
SEEDED_FROM_SOURCES
Seeded from data/raw/ inventories (CHEBI)
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories
-
RESEEDED_FROM_SOURCES
Re-seeded from updated data/raw/ inventories